Gene Therapy Developers Rise on Comments From FDA's Makary

Seeking AlphaApr 21 13:50 ET

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 29% Dive

Simply Wall StApr 19 08:21 ET

REGENXBIO Is Maintained at Neutral by Goldman Sachs

Dow JonesApr 17 13:54 ET · Ratings

Goldman Sachs Maintains Regenxbio(RGNX.US) With Hold Rating, Cuts Target Price to $12

Moomoo NewsApr 17 02:39 ET · Ratings

RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $25

Moomoo NewsApr 4 00:32 ET · Ratings

RBC Cuts Price Target on REGENXBIO to $25 From $30, Keeps Outperform, Speculative Risk

MT NewswiresApr 3 07:19 ET · Ratings